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10 patients with relapsed/refractory HD (n=7), diffuse Large 
B Cell (n=2) and follicular B-cell NHL (n=1) were treated. 
Median age was 41 years (range 20-61) and median number of 
previous lines of therapy was 3 (range 2-4). Conditioning 
chemotherapy consisted of high-dose melphalan 140 mg/sqm 
for all patients except one heavily pre-treated. 
Hypofractionated TLI was delivered as a12 Gy radiotherapy 
course in 3 consecutive daily fractions followed after 2 days 
rest by HDT and hHSCT. A conventional 3D-CRT-TLI plan was 
compared with all HT-TLI plan for all patients. Daily IGRT was 
performed to validate the patients setup margins reliability 
due to the large extension of the target (from the nodal 
chains of the neck to the inguinal ones included the spleen). 
Outcomes measures were treatment related mortality (TRM), 
progression free survival (PFS) and overall survival (OS). 
Results: All patients had chemosensitive disease at salvage 
chemotherapy, with complete remission (CR) obtained in 6 
patients (HD=5, NHL= 1), and partial remission (PR) in 4. 
Conditioning regimen was very well tolerated. All patients 
showed complete engraftment and median time to neutrophil 
and platelet recovery was of 15 (range 9-21) and 17 days 
(range 9-21), respectively. Three patients developed grade 
3/4 mucositis, grade 2 vomiting and 5 reported fever of 
undetermined origin. There was no TRM within the first 100 
days. After a median follow-up of 36 months (range 31 – 44) 
the 3-year PFS and OS were 50% and 90% respectively. In HL 
patients the 3-year PFS was 71% and OS was 100%. HT-TLI in 
comparison with conformal 3D-CRT-TLI reduced the mean 
and the higher (V80%) doses to the organs at risk from 5% to 
76% and from 47% to 100% respectively. The target volume 
was irradiated with higher conformity and homogeneity with 
HT. Measured setup corrections and replanned dose on daily 
MVCT scans showed robustness of the patient immobilization 
technique. 
Conclusions: Although from a limited number of patients, 
this original analysis showed the clinical feasibility of 
hypofractionate HT-TLI with HDT and ASCT. Preliminary 
outcomes in high risk HL shown remarkable efficacy to be 
considered as safe and effective eligible treatment. 
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Purpose/Objective: To analyze toxicities, dosimetry 
parameters, and oncology outcomes in a series of patients 
with retroperitoneal sarcoma treated with Intensity 
Modulated Radiotherapy (IMRT).  
Materials and Methods: Retrospective analysis of 35 
consecutive patients with histologically proven 
retroperitoneal sarcoma treated with IMRT from 2006 to 2013 
in our institution. IMRT was delivered in a step-and-shoot 
technique with daily IGRT. Toxicity was described following 
the CTCAE v4 classification. As several patients had some 
symptoms before IMRT, we made a matched-pair comparison 
(paired-sample sign test) between treatment related 
acute/chronic toxicities and baseline symptoms. Relapse-free 
and survival intervals were estimated by using Kaplan-Meier 
method. 
Results: Median follow up was 28 months. Of the 35 patients 
there were 18 women and 17 men. Median age 57 was years 
(22-74). 19 and 16 patients were treated after extended 
resection, and preoperatively, respectively. 24 patients 
presented a primary tumor, and 11 were treated for a first 
local recurrence. 26 patients presented a liposarcoma (11 G1, 
4 G2 and 11 G3). Median tumor size was 17.5 cm (5-30). 
Median radiotherapy dose was 50.40 Gy with 1.8 Gy fractions. 
Median dosimetry values were: PTV volume 1033cc, 
contralateral kidney 3.68 Gy, and peritoneal Cavity 22.34 Gy. 
The most frequent acute toxicity was gastrointestinal (GI) 
(26/35, mainly G1; 18 patients), followed by lymphopenia 
(22/35, all without clinical significance). Most frequent (no 
clinically relevant) ≥ G2 toxicities were: lymphopenia (n=19), 
GI (n=8) and albumine decrease (n=3). Late ≥ G2 toxicities 
were: GI (n=6), fatigue (n=3), lymphopenia (n=3), kidney 
injury (n=2) and anemia (n=2). In comparison with baseline, 
there were found significant differences in the following 
acute (fatigue [p=0.04], GI [p<0.001], and lymphopenia 
[p<0.001]) and late (≤G2 kidney injury [p=0.008]) toxicities. 
Recurrences were observed in 11 patients: local (n=10), 
sarcomatosis (n=3) and distant (n=5; 2 Lung, 1 Liver, 1 bone, 
1 Node). A salvage treatment was delivered in all patients. 
Median time to local failure was 8 months (0-35). At 2-year, 
disease free survival, locoregional free–survival, and overall-
survival rates were 77%, 82%, and 83%, respectively. 
Conclusions: IMRT for retroperitoneal sarcomas is well 
tolerated with no acute clinically relevant severe toxicity. 
Mild late Kidney injury was observed in 23% pts. Outcomes 
are consistent with those observed in recent studies. The 
ongoing trial EORTC 62092-22092 is awaited to establish the 
true role of high precision preoperative radiotherapy in 
retroperitoneal sarcoma. 
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Purpose/Objective: Craniospinal irradiation (CSI) is indicated 
for various diseases of the central nervous system, such as 
germinoma, medulloblastoma and ependymoma, in curative 
settings, or as palliative treatment in patients with good 
performance status suffering from meningeosis 
carcinomatosa. Due to the irradiation of a very large volume 
and its close proximity to the vertebrae, a major side effect 
of CSI is bone marrow suppression. We performed a 
treatment plan comparison of 3D and IMRT as TomoTherapy 
to evaluate the different techniques regarding bone marrow 
